Document is current
Any future updates will be listed below
-
Authors
Aernout, Ilke https://orcid.org/0000-0002-4604-1575
Verbeke, Rein https://orcid.org/0000-0003-1849-5411
Thery, Fabien
Willems, Patrick
Elia, Uri https://orcid.org/0000-0003-0710-5481
De Smedt, Stefaan C. https://orcid.org/0000-0002-8653-2598
Rappuoli, Rino https://orcid.org/0000-0002-8827-254X
Peer, Dan https://orcid.org/0000-0001-8238-0673
Impens, Francis https://orcid.org/0000-0003-2886-9616
Lentacker, Ine https://orcid.org/0000-0001-7492-6568
- License Information
-
More Information
Article History
Received: 21 August 2023
Accepted: 18 June 2025
First Online: 29 July 2025
Competing interests
: D.P. receives licensing fees (to patents on which he was an inventor), has invested in, consults for (or is on scientific advisory boards or boards of directors) or is a founder and hold shares or conducts sponsored research at Tel Aviv University for the following entities: ART Biosciences, BioNTech SE, Earli Inc., Geneditor Biologics Inc. Kernal Biologics, Merck, Newphase Ltd, NeoVac Ltd, RiboX Therapeutics, Roche, SirTLabs Corporation and Teva Pharmaceuticals Inc. R.R. holds shares in the GSK and Novartis group of companies. The remaining authors declare no competing interests.
